Lyra Therapeutics (Formally 480 Biomedicals) Developing Innovative Therapeutics for ENT Diseases Raises $29.5mn in Series B

Lyra Therapeutics (Formally 480 Biomedicals) Developing Innovative Therapeutics for ENT Diseases Raises $29.5mn in Series B

Shots:

  • This round is led by Perceptive Advisors, RA Capital Management, ArrowMark Partners & Soleus Capital, along with existing investors Polaris Venture Partners, North Bridge Venture Partners & Intersouth Partners
  • Funding will be utilized to plan P-II for LYR-210 in Chronic rhinosinusitis (CRS)
  • Lyra is using its proprietary transmucosal platform for developing treatment for various ENT diseases including LYR-210

Click here to read full press release/ article | Ref: Lyra Therapeutics | Image: Lyra